KI-1125 (Kuhnil Pharmaceutical)

KI-1125 is a small molecule drug candidate being developed by Kuhnil Pharmaceuticals, a South Korean pharmaceutical company. It is specifically designed for the treatment of comorbid hyperlipidemia and hypertension. As of early 2024, the project is in the preclinical stage of development. While specific molecular targets have not been publicly disclosed, the drug likely functions as a fixed-dose combination or a multi-target agent intended to simplify treatment regimens for patients requiring management of both high cholesterol and high blood pressure, which are significant risk factors for cardiovascular disease.